DDW Editor Reece Armstrong speaks to SJ Lee, Founder and CEO of Orum Therapeutics, about the potential of degrader-antibody conjugates (DACs) in treating previously “undruggable” diseases. RA: How do DACs work? SL: Degrader-antibody conjugates (DACs) combine two proven concepts—antibody precision and catalytic protein degradation—into a single, modular medicine. First, a monoclonal antibody carries the DAC […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!